The Future of Immunotherapy is Personal
Personalized Adoptive Cellular Therapy Targeting Neoantigens
A new approach to immunotherapy
PersImmune is a clinical-stage immunotherapy company whose mission is to provide cancer patients with optimized immunotherapy that is personalized on the basis of their own unique tumor signature. Just as no two people are alike, no two cancers are exactly alike; because of this, the same immunotherapy treatment that works for one patient may not work well in another. To address this treatment disparity, PersImmune's proprietary protocol, Personal Adoptive Cellular Therapy for Neoantigens (PACTN) identifies the DNA alterations present in the cancer cells of each patient and generates enriched, tested, highly-specific T-cells that effectively kill the patient’s tumor cells. These are the patient's own cells, and are not edited or genetically engineered which means patients will experience far less side effects than from other methods of immunotherapy or from chemotherapy.
Personalized adoptive cellular therapy has the potential to transform the field of cancer treatment by providing safe, highly-tolerable, effective immunotherapy to cancer patients. Personal immunotherapy - because no two patients are exactly alike.
Eligibility for the Clinical Trial
PersImmune's PACTN clinical trial for MDS patients is being conducted with the UC San Diego Moores Cancer Center and the UC Irvine Chao Family Comprehensive Cancer Center. PersImmune is currently seeking patients for this Phase 1 clinical trial who are age 18 or older and who have suspected or diagnosed MDS.